INOVIQ Schedules Investor Webinar to Review EXO-OC Ovarian Cancer Test Study Results

4 min read | July 08, 2026 12:35 AM AEST | By Aditi Sarkar

INOVIQ Schedules Investor Webinar to Review EXO-OC Ovarian Cancer Test Study Results

Key Points

INOVIQ Limited (ASX:IIQ)
Investor webinar on EXO-OC test study results
Webinar scheduled for 14 July 2026 at 11:00am AEST
Investors to receive updates on development and commercialisation strategies

Summary of INOVIQ's Retrospective EXO-OC Test Study Outcomes

INOVIQ Limited recently concluded a retrospective clinical study evaluating its EXO-OC ovarian cancer test. The company described the study results as disappointing, leading to a detailed technical review aimed at improving future study designs. The EXO-OC test focuses on early ovarian cancer detection, a vital area in cancer diagnostics.

Challenges in securing adequate sample sizes impacted the study's robustness. Despite these obstacles, INOVIQ remains dedicated to refining the EXO-OC test and progressing its development. The test is part of INOVIQ's wider portfolio, which includes diagnostics for ovarian and breast cancers as well as a preclinical CAR-exosome therapeutic program targeting solid tumors.

Details of the Upcoming Investor Webinar

INOVIQ will hold an investor webinar to thoroughly discuss the EXO-OC test study outcomes. The session will cover retrospective study insights, ongoing development efforts, and the commercialisation roadmap. The company aims to address investor concerns and outline measures to mitigate any potential delays in development.

The webinar is scheduled for 14 July 2026 at 11:00am AEST and will be conducted online. Interested investors can register to attend, and a recording will be made available on INOVIQ's website after the event. This briefing offers a valuable opportunity for investors to understand INOVIQ's strategic direction and future initiatives.

EXO-OC Test Commercialisation and Development Strategy

INOVIQ plans to initially commercialise the EXO-OC test as a Laboratory Developed Test (LDT) in the United States. Subsequently, the company intends to develop the test into an In Vitro Diagnostic (IVD) for expanded ovarian cancer screening. This phased strategy aims to accelerate market entry while ensuring thorough validation.

The update highlights INOVIQ's focus on enhancing the EXO-OC test and its algorithm to improve accuracy and reliability, which are critical for successful clinical adoption and commercial success.

Challenges and Prospects in Ovarian Cancer Diagnostics

The disappointing retrospective study results underscore the challenges inherent in cancer diagnostic development, particularly in obtaining sufficient and robust samples. INOVIQ's proactive technical review and refinement efforts demonstrate its commitment to overcoming these hurdles.

Despite these difficulties, the market potential for effective ovarian cancer diagnostics remains substantial. Early detection is essential for improving patient outcomes, and innovations like the EXO-OC test represent significant progress. INOVIQ's ongoing innovation and development efforts position it well to seize opportunities in the expanding cancer diagnostics sector.

INOVIQ's Comprehensive Product Portfolio and Industry Standing

INOVIQ is recognized for its leadership in exosome technology, offering a diverse range of products spanning diagnostics and therapeutics. Its portfolio includes commercial-stage exosome isolation products and clinical-stage diagnostics for ovarian and breast cancers, alongside a preclinical CAR-exosome therapeutic program for solid tumors.

This integrated approach to cancer care, combining diagnostics with therapeutics, highlights INOVIQ's dedication to advancing cancer treatment and enhancing patient outcomes. The company's innovative solutions and strategic focus on impactful areas position it as a key player in the evolving cancer care market.

Investor Outlook: Key Developments to Monitor

Investors tracking INOVIQ should focus on the forthcoming investor webinar for updates on the EXO-OC test’s development and commercialisation plans. How the company addresses challenges identified in the retrospective study will be pivotal for sustaining investor confidence and achieving strategic goals.

Additionally, monitoring INOVIQ's progress in refining its diagnostics and expanding its market footprint will be essential. As the company continues to innovate and adapt, its efforts to enhance shareholder value and drive long-term growth remain central to its strategy.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.